R&D InvestmentSignificant R&D investment underscores commitment to innovation, potentially leading to breakthrough products and future revenue streams.

Industry PotentialThe artificial heart market has significant potential, with increasing demand for advanced cardiovascular solutions, positioning the company for future growth.

Bears Say

Negative Cash FlowPersistent negative cash flow indicates high funding needs, which could strain resources and limit operational flexibility until commercialization.

Equity ErosionDeclining equity reflects ongoing financial strain, diluting shareholder value and potentially impacting future capital raising efforts.

Pre-Revenue StageOperating without revenue limits financial sustainability and increases reliance on external funding, posing risks until product commercialization.

HEART FAQ

What was Scandinavian Real Heart AB’s price range in the past 12 months?

Scandinavian Real Heart AB lowest stock price was kr11.51 and its highest was kr29.89 in the past 12 months.

What is Scandinavian Real Heart AB’s market cap?

Scandinavian Real Heart AB’s market cap is kr139.46M.

When is Scandinavian Real Heart AB’s upcoming earnings report date?

Scandinavian Real Heart AB’s upcoming earnings report date is Feb 19, 2026 which is today.

How were Scandinavian Real Heart AB’s earnings last quarter?

Currently, no data Available

Is Scandinavian Real Heart AB overvalued?

According to Wall Street analysts Scandinavian Real Heart AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Scandinavian Real Heart AB pay dividends?

Scandinavian Real Heart AB does not currently pay dividends.

What is Scandinavian Real Heart AB’s EPS estimate?

Scandinavian Real Heart AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Scandinavian Real Heart AB have?

Scandinavian Real Heart AB has 9,997,408 shares outstanding.

What happened to Scandinavian Real Heart AB’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Scandinavian Real Heart AB?

Currently, no hedge funds are holding shares in SE:HEART

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Scandinavian Real Heart AB

Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. It engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, PulsePump, and Sternal Prosthesis products. The company was incorporated in 2007 and is based in Västerås, Sweden.